Physician review
Prescription decisions begin with medical-history and contraindication review by Dr. Anjmun Sharma, MD.
✓ Medically reviewed by Dr. Anjmun Sharma, M.D., Updated May 2026
A Wegovy Alternative That Won't Break the Bank
The dispensing pharmacy label identifies the compounded preparation as semaglutide. It is a different product from FDA-approved brands, is not FDA-approved or brand-identical, and results vary.
wegovy alternativewegovy cliniccheaper than wegovywegovy without insurancealternatives to wegovy
Quick answer
The dispensing pharmacy label identifies the compounded preparation as semaglutide. It is a different product from FDA-approved brands, is not FDA-approved or brand-identical, and results vary. New Hope Weight Loss is not affiliated with Novo Nordisk or the Wegovy brand; our cash-pay compounded semaglutide programs start at $166 per month with no insurance required and a $119 telehealth consultation to begin.
Important: Compounded semaglutide and tirzepatide are not FDA-approved and are not brand-identical. Eligibility and results vary.
Costs less than your daily coffee.
A daily latte~$6/day
Your weight-loss plan$5.50/day$39/week
$166 a month, physician-supervised, no insurance needed.
Why People Look for a Wegovy Alternative
Wegovy® is a registered trademark of Novo Nordisk A/S and is approved by the FDA for specific uses. But for many people it's hard to get: list prices can exceed $1,000/month without insurance, coverage is inconsistent, and the 2024-2025 shortages showed how unreliable access can be. That's why so many search for a more accessible alternative.
New Hope Weight Loss is not affiliated with Novo Nordisk A/S. The dispensing pharmacy label identifies the compounded preparation as semaglutide. It is a different product from FDA-approved brands, is not FDA-approved or brand-identical, and results vary.
How the Compounded Option Compares
| Brand-name Wegovy | Compounded Semaglutide at NHWL | |
|---|---|---|
| Active ingredient | Semaglutide | Label identifies semaglutide; separate compounded product |
| Typical monthly cost | $1,000+ (no insurance) | from $166/mo |
| Physician supervision | Varies | Always, Dr. Sharma |
| FDA-approved product | Yes | No (compounded) |
| Insurance required | Often | Never |
Compounded medications are not FDA-approved products, are not brand-identical, and results vary. Any prescription requires individualized medical review and lawful pharmacy fulfillment. Dr. Sharma will tell you honestly whether you're a good candidate.
What You Pay at New Hope Weight Loss
- $119 one-time, Dr. Sharma's review + first prescription.
- $499 for a 3-month plan = $166/month.
- $199 one-month trial to start small.
HSA/FSA accepted. Klarna and Affirm financing available. No insurance, ever.
Estimate Your Savings
Frequently asked questions
Is there a cheaper alternative to Wegovy?
The dispensing pharmacy label identifies the compounded preparation as semaglutide. It is a different product from FDA-approved brands, is not FDA-approved or brand-identical, and results vary. Compounded medications are not FDA-approved and are not identical to the brand, but they are a legal, supervised, more accessible option.
Can I get Wegovy without insurance?
Brand-name Wegovy typically requires insurance or out-of-pocket payment exceeding $1,000/month. New Hope Weight Loss never requires insurance, compounded semaglutide is cash-pay from $166/month with HSA/FSA accepted.
Is the compounded version the same as Wegovy?
The dispensing pharmacy label identifies the compounded preparation as semaglutide. It is a different product from FDA-approved brand products, is not FDA-approved or brand-identical, and results vary. Any prescription requires Dr. Sharma's review and depends on lawful pharmacy fulfillment for the patient's location.
How do I switch from Wegovy to the compounded option?
Take our 2-minute quiz and complete the medical intake form. Tell Dr. Sharma about your current dose and history; she'll determine the right starting plan and supervise the transition.
Transparent pricing
$166/month
About $5.50 a day, less than a daily latte
A fraction of brand-name GLP-1 list prices, which often run $900 to $1,300 or more a month.
- Licensed U.S. physician, supervised the whole way
- Compounded semaglutide included
- Only if a prescription is approved and the dispensing pharmacy can fulfill it for your location, the pharmacy confirms packaging and shipping details before fulfillment
- Ongoing dose adjustments and support
- No insurance needed, HSA and FSA plus financing accepted
$119 one-time to get started with your physician consultation.
Medical disclaimer: Individual results may vary. GLP-1 medications require a physician prescription and ongoing supervision. Clinical trial results cited are averages; not all patients achieve the same outcomes. Eligibility is determined during the medical consultation. This information does not replace professional medical advice.
New Hope Weight Loss | 1503 South Coast Drive, Suite 322, Costa Mesa, CA 92626 | (657) 837-3342
Wegovy® and Ozempic® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. New Hope Weight Loss is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly. Compounded semaglutide and tirzepatide are not FDA-approved or brand-identical and have not undergone FDA premarket review for safety, effectiveness, or quality. Results vary. Any prescription depends on individualized medical review and lawful pharmacy fulfillment for the patient's location.
Wegovy's FDA Label: Weight Reduction, Heart Risk, and a Liver Indication Ozempic Does Not Carry
Wegovy and Ozempic are both semaglutide, both are registered trademarks of Novo Nordisk A/S, and New Hope Weight Loss is not affiliated with, endorsed by, or sponsored by Novo Nordisk. The difference is not the molecule. It is what the FDA reviewed and approved each product to do.
Wegovy injection is approved, with a reduced calorie diet and increased physical activity, to reduce excess body weight and maintain that reduction long term in adults with obesity and in adults with overweight who have at least one weight-related health condition. Among semaglutide products, only the Wegovy injection carries a pediatric indication, for patients aged 12 and older with obesity. Wegovy also carries a cardiovascular indication that does not require diabetes: reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. In August 2025 the FDA granted accelerated approval for noncirrhotic MASH, a form of fatty liver disease, with moderate to advanced fibrosis in adults. The Ozempic label covers a different job: blood sugar in adults with type 2 diabetes, plus kidney and heart outcomes in that group.
Those approvals belong to the brand. The compounded semaglutide prescribed for our patients and prepared by a licensed pharmacy is a separate product: not FDA-approved, not brand-identical, not a generic, and not interchangeable with the brand, and results vary. Brand trial findings do not predict what a compounded preparation will do for any one person. Dr. Sharma reviews your history and says honestly whether this is an appropriate option. Our program is for adults 18 and older.
Wegovy and Ozempic are both semaglutide. Why is only one of them approved for weight management?
Because they were submitted to the FDA as separate products, with separate trial programs and separate labeled dose ranges. The Wegovy application was built around long-term weight reduction, and later around cardiovascular risk in adults with obesity or overweight and around noncirrhotic MASH with fibrosis. The Ozempic application was built around blood sugar in type 2 diabetes, and later kidney and heart outcomes in that group. The FDA approves the evidence submitted for a product, not a molecule in the abstract.
I have fatty liver disease. Does the Wegovy MASH approval mean compounded semaglutide will treat my liver?
No. The August 2025 accelerated approval covers brand Wegovy in adults with noncirrhotic MASH and moderate to advanced fibrosis, and it rests on evidence generated for that brand product. A compounded semaglutide preparation is not FDA-approved for MASH or for anything else, is not brand-identical, and results vary. Liver disease deserves its own workup and often its own specialist. Tell Dr. Sharma about it so it becomes part of the medical review.
Wegovy now comes as a pill and as a higher-strength injection. Does that change what the compounded option is?
No. The Novo Nordisk Wegovy line has grown. The FDA approved Wegovy tablets, an oral form of semaglutide for chronic weight management in adults, and in March 2026 approved a higher-strength injection called Wegovy HD. Each went through its own FDA review as a brand product. A compounded semaglutide preparation is none of them, is not FDA-approved or brand-identical, and nothing in a brand label describes what your plan here would be.